RCUS — Arcus Biosciences, Inc.

Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$2.20B

P/E Ratio

-6.64

Beta

0.92

52-Week Range

6.5-26.4

Dividend Yield

$0.00

CEO

Terry J. Rosen

Employees

627

IPO Date

Mar 15, 2018

Exchange

NYSE